<PAGE> 1
--------------------------------
OMB APPROVAL
--------------------------------
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response.........14.90
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ____________)*
CALYPTE BIOMEDICAL CORPORATION
________________________________________________________________________________
(Name of Issuer)
COMMON STOCK
________________________________________________________________________________
(Title of Class of Securities)
0000899426
________________________________________________________________________________
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing of this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
SEC 1745 (2-95)
Page 1 of 5 Pages
<PAGE> 2
SCHEDULE 13G
- --------------------- -----------------
CUSIP NO. 0000899426 Page 2 of 5 Pages
- --------------------- -----------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON WILLIAM BOEGER/QUEST VENTURES
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
###-##-#### / 943008578
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Berkeley, California
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
723,322 common shares 6.9%
NUMBER OF -------------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -------------------------------------------------------------
EACH REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 723,322 common shares 6.9%
WITH -------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
William Boeger 723,322 common shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
William Boeger 6.9%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
William Boeger IN
Quest Ventures PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE> 3
CUSIP No. 0000899426 Page 3 of 5 Pages
----------
ITEM 1.
(a) Name of Issuer CALYPTE BIOMEDICAL CORPORATION
(b) Address of Issuer's Principal Executive Offices
1440 Fourth Street
Berkeley, Ca. 94710
ITEM 2.
(a) Name of Person Filing WILLIAM BOEGER/QUEST VENTURES
(b) Address of Principal Business Office or, if none, Residence
126 South Park, San Francisco, CA 94107
(c) Citizenship
USA
(d) Title of Class of Securities
COMMON STOCK
(e) CUSIP Number
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b),
CHECK WHETHER THE PERSON IS A:
(a) / / Broker or Dealer registered under Section 15 of the Act
(b) / / Bank as defined in section 3(a)(6) of the Act
(c) / / Insurance Company as defined in section 3(a)(19) of the Act
(d) / / Investment Company registered under section 8 of the Investment
Company Act
(e) / / Investment Adviser registered under section 203 of the
Investment Advisers Act of 1940
(f) / / Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act of
1974 or Endowment Fund, see section 240.13d-1(b)(1)(ii)(F)
(g) / / Parent Holding Company, in accordance with section 240.13d-
1(b)(1)(ii)(G) (Note:See Item 7)
(h) / / Group, in accordance with section 240.13d-1(b)(1)(ii)(H)
ITEM 4. OWNERSHIP
(a) Amount Beneficially Owned
WILLIAM BOEGER 723,322 common shares(1)
(b) Percent of Class
WILLIAM BOEGER 6.9%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote, Mr. Boeger:
723,322 common shares
(ii) shared power to vote or direct the vote
(iii) sole power to dispose or direct the disposition of
Mr. Boeger: 723,322 common shares
(iv) shared power to dispose or direct the disposition of
(1) 220,000 shares are in the name of William Boeger and
503,322 shares are in the name of Quest Ventures
<PAGE> 4
CUSIP No. 0000899426 Page 4 of 5 Pages
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following / /.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
<PAGE> 5
CUSIP No. 0000899426 Page 5 of 5 Pages
ITEM 10.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course
of business and were not acquired for the purpose of and do not have the effect
of changing or influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in any transaction
having such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct. We agree to file this 13G together.
February 14, 1997
-------------------------------
Date
/s/ WILLIAM BOEGER
-------------------------------
Signature
William Boeger
-------------------------------
Name/Title
February 14, 1997
-------------------------------
Date
-------------------------------
Signature
Quest Ventures
-------------------------------
Name/Title
